CANbridge Pharmaceuticals Inc. announced the resignation of Dr. Fangxin Li as a non-executive director and member of the remuneration committee, effective June 25, 2025, due to changes in his work arrangements. Consequently, the proposed re-election of Dr. Li will be withdrawn from the agenda of the upcoming AGM. The board's composition remains unchanged in terms of executive and independent non-executive directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.